The Potential of Personalized/Precision Medicine for Meningiomas

• Published in: Nō shinkei geka Vol. 50; no. 1; p. 132
• Main Authors: Yamaguchi, Shigeru, Fujimura, Miki
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.01.2022
• Subjects: Humans; Meningeal Neoplasms - genetics; Meningeal Neoplasms - therapy; Meningioma - genetics; Meningioma - therapy; Mutation; Precision Medicine
• ISSN: 0301-2603; 1882-1251
• DOI: 10.11477/mf.1436204538

Meningiomas are one of the most common primary brain tumors. The majority of patients with meningiomas can undergo curative resection or remain asymptomatic for a lifetime, but a minority of them have tumors with cumbersome clinicopathological features causing life-threatening disease. Although several cytotoxic agents and hormonal therapies have been tried for refractory and unresectable meningiomas, there are no effective drugs available for meningiomas so far. In the last decade, due to the rapid progress in comprehensive genomic research for individual tumors, novel somatic and recurrent mutations were discovered in meningiomas. The discovered somatic mutations were mostly mutually exclusive with gene alterations, and importantly, several of these mutations, such as and , are potentially actionable mutations for precision/personalized medicine. In addition, immunotherapy is another attractive treatment option for refractory meningiomas due to the development of immune checkpoint inhibitors. Herein, we describe the possibility of precision medicine for meningiomas according to each molecular aberrancy and present the currently ongoing clinical trials including hormonal therapy, targeted kinase inhibitors, and immunotherapy.